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Abstract
BACKGROUND & AIMS—Patients with celiac disease have been reported to be at increased
risk for pancreatitis and pancreatic insufficiency, but the risk might have been overestimated
because of patient selection and limited numbers of patients for analysis. Furthermore, no
distinction has been made between patients with gallstone-related and non gallstone-related
pancreatitis. We performed a nationwide study to determine the risk for any pancreatitis or
subtype of pancreatitis among patients with biopsy-verified celiac disease.
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METHODS—We analyzed data from patients in Sweden with celiac disease (n=28,908),
identified based on small intestinal biopsy records from 28 pathology departments (those with
villous atrophy, Marsh 3). Biopsies were performed from 1969 to 2008 and biopsy report data
were collected from 2006 to 2008. Patients with pancreatitis were identified based on diagnostic
codes in the Swedish Patient Register and records of pancreatic enzyme use in the Swedish
Prescribed Drug Register. Data were matched with those from 143,746 individuals in the general
population; Cox regression was used to estimate hazard ratios (HRs) for pancreatitis.
RESULTS—We identified 406 individuals with celiac disease who were later diagnosed with
pancreatitis (and 143 with expected pancreatitis) (HR=2.85; 95% confidence interval [CI], 2.53–
3.21). The absolute risk of any pancreatitis among patients with celiac disease was 126/100,000
person-years with an excess risk of 81/100,000 person-years. The HR for gallstone-related acute
pancreatitis was 1.59 (95% CI, 1.06–2.40), for non-gallstone-related acute pancreatitis was 1.86
(1.52–2.26), for chronic pancreatitis was 3.33 (95% CI, 2.33–4.76), and for supplementation with
pancreatic enzymes was 5.34 (95% CI, 2.99–9.53). The risk of any pancreatitis within 5 years of
diagnosis was 2.76 (95% CI, 2.36–3.22).
CONCLUSIONS—Based on an analysis of medical records in Sweden, patients with celiac
disease were at an almost 3-fold increase in risk of developing pancreatitis.
Keywords
Coeliac Disease; Celiac Disease; Cohort study; Inflammation; Pancreatitis; Epidemiology;
retrospective analysis; gluten intolerance; complication
Introduction
Celiac disease is an autoimmune disorder that occurs in about 1% of the Western population.
The disease is triggered by gluten exposure in genetically predisposed individuals1 and the
only treatment is a lifelong gluten-free diet.
To our knowledge, the effect of celiac disease on pancreatic function is poorly understood.
Macroamylasemia is five times more common in patients with active celiac disease than in
healthy controls.2 Celiac disease is also overrepresented among patients with recurrent acute
pancreatitis.3 Between 10 and 20% of patients with newly diagnosed celiac disease are
likely to experience pancreatic insufficiency.4, 5 Supplementation of pancreatic enzymes in
patients with celiac disease and chronic diarrhea expressing low fecal elastase indicating
chronic pancreatic insufficiency, improved problems with diarrhea in 18 of 20 individuals.4
All of these patients experienced histopathological improvement.4, 6 In one study
investigating the association between celiac disease and pancreatitis patients with celiac
disease had a 20-fold elevated risk of chronic pancreatitis and a 3-fold higher risk of acute or
chronic pancreatitis.7 However, that study included only hospitalized patients with celiac
disease, potentially leaving out those diagnosed and treated on an outpatient basis.
Furthermore, celiac disease was not validated histopathologically. Finally, no distinction
was made between gallstone- and non-gallstone-related acute pancreatitis.
The main objective of this study was therefore to estimate the risk of any pancreatitis,
including subtypes of pancreatitis, in patients with biopsy-verified celiac disease.
Methods
We linked data on biopsy reports with celiac disease to the Swedish Patient Register
(containing both inpatient and hospital outpatient data) and the Swedish Prescribed Drug
Register.
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Celiac Disease
Patients with celiac disease were identified from biopsy reports performed between 1969
and 2008 in any of Sweden’s 28 pathology departments (Table 1). Celiac disease was
defined as having villous atrophy (VA, equivalent to Marsh grade 3, see appendix).8
Although we did not request positive celiac disease serology for the diagnosis of celiac
disease, in a random sample of patients undergoing patient chart reviews 88% (n=71/81)
with available data on celiac disease serology were serologically positive before biopsy.9
At each pathology department, IT personnel identified relevant biopsy reports from
computerized databases and delivered data on biopsy date, personal identity number of the
patient,10 morphology according to the Swedish SnoMed classification codes
(Supplementary Table E1) and topography (duodenum and jejunum). Because searches were
restricted to computerized databases, most of our biopsy report data originated from 1990 or
later (Table 1).
This paper was based on the same celiac disease cohort as in our paper on mortality in celiac
disease (n=29,096, Figure 1).11 Each of the 29,096 individuals with celiac disease was then
matched with five reference individuals from the general population of Sweden (n=144,522)
(matching on age, sex, calendar year and county of residence). Exclusions because of data
irregularities are shown in Figure 1.
We then excluded individuals with a diagnosis of pancreatitis or a record of pancreatic
enzyme supplementation before celiac disease diagnosis or study entry. The main analyses
of this paper were based on 28,908 individuals with celiac disease and 143,746 matched
reference individuals (Figure 1).
For comparative purposes, we also identified individuals undergoing small intestinal biopsy
but without VA (inflammation, Marsh 1–2, n=13,306) and individuals with normal mucosa
but positive IgA/IgG gliadin or endomysium or tissue transglutaminase antibodies (n=3,719,
the majority of these individuals had tested positive for IgA gliadin). These two cohorts
were identical to those in our paper on mortality in celiac disease.11 We then excluded
anyone with a prior diagnosis of pancreatitis. Individuals undergoing small intestinal biopsy
but without VA were used as secondary reference individuals.
Pancreatitis
We defined pancreatitis according to relevant International Classification of Disease (ICD)
codes (see appendix). Pancreatitis was ascertained from both inpatient and hospital-based
outpatient data (Swedish Patient Register)12, and the Swedish Prescribed Drug Register.
Hence, in this study pancreatitis represents patients who were diagnosed with clinical
pancreatitis plus those who received pancreatic enzymes presumably for pancreatic
insufficiency.
We distinguished between gallstone-related acute pancreatitis, non-gallstone-related acute
pancreatitis, and chronic pancreatitis. Gallstone-related pancreatitis was defined as having
either a specific ICD-10 code (K85.1) or a combination of a code for acute pancreatitis
(ICD7-10) and cholecystectomy, ERCP or cholecystotomy (see appendix). In this study
patients who had gallstone-related pancreatitis at any stage were not included in the non-
gallstone group. Use of pancreatic enzyme (ATC code A09AA02) was also considered proof
of pancreatic insufficiency.
When looking specifically at celiac disease and the risk of supplementation of pancreatic
enzymes, we restricted our analysis to patients entering the study (having a biopsy) on 1 July
2005 or later in that the Swedish Prescribed Drug Register began on this date. In the analysis
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of “any pancreatitis”, also these individuals who had a biopsy date before 1 July 2005 and
later pancreatic enzyme supplementation were counted as positive for “any pancreatitis”
since they had been at risk of a pancreatitis diagnosis also before 1 July 2005 (e.g. from
gallstone-related pancreatitis).
Covariates
Any diabetes (type 1 or type 2) was identified through the Swedish Patient Register (see
appendix for ICD codes). This register was also used to define alcohol-related disease and
chronic obstructive lung disease (as a proxy for heavy smoking). Education was divided into
four categories. Socio-economic status was ranked in line with the European Socio-
economic Classification (ESeC, 7 categories).13 The ESeC version we used was based on
occupation. Country of birth was classified as Nordic vs. non-Nordic.
Statistics
We used Cox regression to estimate HRs for pancreatitis (any, acute gallstone-related, acute
non-gallstone-related, chronic pancreatitis and use of pancreatic enzymes). We used an
internally stratified Cox regression model in which only individuals within each stratum
were compared before a summary risk estimate was estimated. We could therefore eliminate
the influence of age, sex, county of residence and calendar year because participants in each
stratum were identical on these parameters.
Follow-up time started on the date of the first biopsy with VA (celiac disease diagnosis) and
on the corresponding date in the matched reference individuals. It ended with a diagnosis of
pancreatitis, death, emigration, or on 31 December 2009, whichever occurred first.
We also evaluated the risk of any pancreatitis (and our subtypes of pancreatitis) by time
since diagnosis (<1 year, 1- <5 years and ≥5 years), sex, age at celiac disease diagnosis (10–
19, 20–39, 40–59 and ≥60 years at first biopsy) and calendar period of the first biopsy with
celiac disease (-1989, 1990–1999 and 2000). Incidence rates were calculated by dividing the
number of person-years at risk with the number of first pancreatitis events and attributable
risks (%) as (1-1/HR). We also examined the risk of pancreatitis after adjusting for diabetes
mellitus, alcohol-related diagnosis codes, chronic obstructive lung disease, education, socio-
economic position and country of birth.
Secondary Analyses
In a separate analysis, to account for the severity of acute pancreatitis, we restricted our
outcome to those with a hospital stay ≥14 days or those with in-hospital mortality. In a
subanalysis we also restricted our outcome of “any pancreatitis” to individuals with a
diagnosis of any pancreatitis in the Patient Register (not counting pancreatic enzyme
substitution as pancreatitis).
We compared the risk of any pancreatitis in biopsy-proven celiac disease vs. that in
individuals without VA (13,106 with inflammation (Marsh 1–2)8; and 3,690 with normal
mucosa (Marsh 0)8 but positive serology to gliadin, endomysium or tissue transglutaminase
antibodies, n=3,690). These analyses were adjusted for age, sex and calendar period.
Lastly, we examined the proportion of celiac disease individuals and reference individuals
having a diagnosis of pancreatitis occurring before celiac disease diagnosis and study entry.
In this case-control study we used conditional logistic regression to calculate odds ratios
(ORs) for an earlier pancreatitis diagnosis in celiac disease.
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Statistical significance was defined as 95% confidence intervals (CIs) for risk estimates not
including 1.0. SPSS 18.0 software was used for the statistical analysis.
Ethics
This project (2006/633-31/4) was approved by the Research Ethics Committee of the
Karolinska Institute, Sweden (14 June 2006).
Results
Background data
The median age at first biopsy and celiac disease diagnosis was 30 years (range 0–95). Some
86% of individuals with celiac disease had been biopsied in 1990 or later. The majority of
celiac disease patients were female (Table 1). We identified 406 individuals with celiac
disease who were later diagnosed with pancreatitis (expected: n=143). Some 199 (49.0%) of
these were identified through the Patient Register with a diagnosis code for acute or chronic
pancreatitis, with another 207 (51%) through the Prescribed Drug Register, who received
supplementation of pancreatic enzymes. Of patients with a diagnosis of any pancreatitis in
the Patient Register, 144 (72%) had only an inpatient diagnosis, 16 (7.7%) only an
outpatient diagnosis, and 39 (19.6%) both an inpatient and an outpatient diagnosis.
Celiac disease and future risk of any pancreatitis
Individuals with celiac disease were at increased risk of later pancreatitis (HR=2.85; 95%
CI=2.53–3.21)(Table 2). The absolute risk of any pancreatitis was 126/100,000 person-years
with an excess risk of 81/100,000 person-years. HRs for any pancreatitis were similar in
men and women (p for interaction between celiac disease and sex=0.994)(Table 3).
Although HRs for any pancreatitis were higher in patients diagnosed with celiac disease
before age 40 years, the difference between age groups did not attain statistical significance
(p for interaction between celiac disease and age=0.194).
Gallstone-related acute pancreatitis
Some 30 patients with celiac disease had a later diagnosis of gallstone-related acute
pancreatitis (expected n=19)(Table 2), resulting in a HR of 1.59 (95% CI=1.06–2.40). The
absolute risk of gallstone-related acute pancreatitis was 9/100,000 person-years with an
excess risk of 3/100,000 person-years. Women with celiac disease were at a non-significant
excess risk of gallstone-related acute pancreatitis (HR=1.37; 95% CI=0.83–2.28) compared
with a 2.21-fold increased risk in men (95% CI=1.09–4.45)(Supplementary Table E2).
Non-gallstone-related acute pancreatitis
Some 133 patients with celiac disease had a later diagnosis of non-gallstone-related acute
pancreatitis (expected n=72). The corresponding HR was 1.86 (95% CI=1.52–2.26)(Table
3). The absolute risk of non-gallstone-related acute pancreatitis was 41/100,000 person-
years with an excess risk of 19/100,000 person-years. The highest HRs for non-gallstone-
related acute pancreatitis were seen in celiac disease patients diagnosed before age 40 years
(Supplementary Table E3).
Chronic pancreatitis
Patients with celiac disease were at increased risk of chronic pancreatitis (HR=3.33; 95%
CI=2.33–4.76, based on 49 observed cases vs. 15 expected)(Table 2). The absolute risk of
non-gallstone-related acute pancreatitis was 15/100,000 person-years with an excess risk of
11/100,000 person-years. See also Supplementary Table E4.
Sadr-Azodi et al. Page 5
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2013 October 01.
$watermark-text
$watermark-text
$watermark-text
Supplementation with pancreatic enzyme
Restricting our dataset to patients entering the study (having a biopsy with VA) on 1 July
2005 or later, patients with celiac disease were at a 5.34-fold increased risk of receiving
supplementation with pancreatic enzyme products after celiac disease diagnosis (95%
CI=2.99–9.53, based on 21 observed cases vs. 4 expected)(Table 2). Given that this analysis
was restricted to the years 2005–2009, we did not estimate calendar-specific HRs.
Supplementary Table E5 shows additional data.
Secondary analyses
None of the above risk estimates changed after adjusting for country of birth, socioeconomic
position, level of education, chronic obstructive lung disease or alcohol-related diseases
(data not shown), except that the HR for chronic pancreatitis in celiac disease rose to 4.96
after adjustment (95% CI=3.18–7.76). Restricting our outcome of any pancreatitis to
individuals with this diagnosis in the Patient Register the HR was 2.02 (95%CI=1.71–2.37).
Patients with celiac disease were also at increased risk of severe acute pancreatitis
(gallstone-related: HR=3.18; 95% CI=1.46–6.90 and non-gallstone related: HR=2.00; 95%
CI=1.16–3.44).
Individuals with celiac disease were at lower risk of any pancreatitis than individuals with
inflammation but no villous atrophy (HR=0.73; 95% CI=0.55–0.92) and individuals with
normal mucosa but positive celiac disease serology (HR=0.71; 95% CI=0.63–0.85). In a
post-hoc analysis we found that these differences were due to large differences in the risk of
pancreatitis in the first year after biopsy. The HR for any pancreatitis during the first year
after celiac disease diagnosis was 12.03 (95% CI=8.15–17.75) in patients with inflammation
(Marsh 1–2) and 9.81 (95% CI=5.16–18.62) in patients with normal mucosa but positive
celiac disease serology. The relative risks of pancreatic enzyme supplementation were
especially high. In the first year after biopsy patients with inflammation (Marsh 1–2) were at
an almost 38-fold increased risk of being prescribed pancreatic enzymes compared with the
general population (HR=37.67; 95% CI=15.23–93.16). Further, those with normal mucosa
but positive celiac disease serology were at an almost 90-fold increased risk to receive such
enzymes in the first year after biopsy (HR=88.88; 95% CI=18.89–418.08).
Pancreatitis occurring before celiac disease
Individuals with celiac disease were at a 2.59-fold increased risk of having pancreatitis
before first biopsy with VA (95% CI=2.19–3.07). This excess risk was made up of earlier
non-gallstone-related acute pancreatitis (OR=2.32; 95% CI=1.88–2.88), chronic pancreatitis
(OR=3.79; 95% CI=2.78–5.16), but also an increased risk of earlier dietary supplementation
with pancreatic enzymes (OR=5.02; 95% CI=2.74–9.20). In contrast, celiac disease patients
were at no increased risk of earlier gallstone-related acute pancreatitis (OR=1.37; 95%
CI=0.79–2.38).
Post-hoc analyses
Additional data are reported in the appendix.
Discussion
In the current study we have used data from histological reports, providing a robust
classification of celiac disease. This also enabled us to identify individuals with a small
intestinal biopsy without VA, who then served as secondary controls. The large sample size
made it possible to study acute and chronic pancreatitis separately. Furthermore we were
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able to analyze the time trends in the occurrence of pancreatitis in relation to the diagnosis
of celiac disease.
This study found a 2–3-fold increased risk of pancreatitis in patients with celiac disease.
Risk estimates were low for gallstone-related acute pancreatitis and high for pancreatic
insufficiency, necessitating pancreatic enzyme supplementation. The highest risks were
generally noted in the first year of biopsy, especially for chronic pancreatitis and enzyme
supplementation.
To our knowledge, only one population-based study has investigated the association
between celiac disease and pancreatitis.7 In the current study we were able to stratify the
analyses based on time since celiac disease diagnosis. Although surveillance bias may have
contributed to our risk estimates, it is unlikely to explain the positive association between
celiac disease and pancreatitis in that risk estimates were increased even more than 5 years
after celiac disease diagnosis.
We distinguished between gallstone and non-gallstone related acute pancreatitis. As
expected given the relatively young age of those with celiac disease diagnosis, non-gallstone
related acute pancreatitis was more than 4 times more common as compared to the
gallstone-related disease. There was however no difference in the relative risk of these two
entities of acute pancreatitis. This might indicate a shared common cause in both entities of
the disease in patients with celiac disease. The risk in excess of that expected from gallstone
acute pancreatitis may also be related to celiac disease related pancreatic or papillary
pathology.
Importantly, between 10 and 20% of newly diagnosed patients with celiac disease may
experience pancreatic insufficiency.4, 5 Thus the observed risk estimates can be regarded as
considerably lower than expected.
Several factors might contribute to the association between celiac disease and pancreatitis.
Malnutrition is known to impair the pancreatic section and structural changes, including
acinar atrophy, in the pancreas.14 VA is associated with pancreatic insufficiency and
restored pancreatic enzyme levels are observed after introduction of a gluten-free diet.15 The
altered levels of autoregulatory enteric hormones (such as cholecystokinin) might also be a
contributing factor.15 Celiac disease also leads to papillary inflammation and stenosis that
could sensitize the pancreas to develop acute pancreatitis.3 Persistent inflammation and
irreversible changes to the pancreatic structure and function might contribute to the long-
term increased risk of pancreatitis in patients with celiac disease. Finally, the two diseases
may share immunological characteristics in the sense that Th1-associated cytokines are
increased in both celiac disease and pancreatitis.16, 17
The main strength of this paper is its population-based design and size, which provided the
statistical power to stratify the analyses by age, sex and calendar period. None of these
factors, however, interacted with celiac disease regarding the risk of pancreatitis. We were
also able to adjust our analysis for a number of potential confounders, including diabetes,
alcohol-related disease, socio-economic position, education and country of birth. A second
strength is our use of biopsy report data to identify cases with celiac disease. Biopsy reports
with VA have a high positive predictive value for celiac disease (95%), and more than 96%
of gastroenterologists and pediatricians in Sweden perform a biopsy in at least 9 of 10
patients with suspected celiac disease before diagnosis.9
Elevated levels of serum amylase might occur asymptomatically in patients with celiac
disease.2 The diagnosis of acute pancreatitis in a general population has been recently
validated in the Swedish Patient Register and the positive predictive value was 98%.18
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Nevertheless, the positive predictive value of serum amylase or lipase in diagnosing acute
pancreatitis among patients with celiac disease is unknown. However, because the diagnosis
of acute pancreatitis is based on a combination of elevated serum amylase or lipase and
clinical symptoms, including abdominal pain, it is unlikely that our results are biased by
false-positive cases. Still it should be noted that the associations remained significantly
higher than expected even after excluding pancreatic enzyme supplementation from our
outcome. Furthermore, supplementation of pancreatic enzymes may be necessary initially in
patients with CD due to reversible pancreatic insufficiency. This is resolved in most patients
after introduction of gluten-free diet and is not per se be defined as chronic pancreatitis.4
This increased risk was evident even after excluding the first year of follow-up indicating
that some patients might in fact have chronic pancreatitis.
Conclusion
In conclusion, we found a moderately increased risk of pancreatitis in patients with celiac
disease. This statistically significant association was seen even after excluding patients
identified though prescribed drug register. Future studies should focus on potential
mechanisms underlying the association between celiac disease and pancreatitis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Flow chart of study participants
CD, Celiac disease
* Inflammation (intraepithelial lymphocytosis) equals Marsh 1–2
# Normal mucosa with positive IgA/IgG endomysium, transglutaminase or gliadin
antibodies.
§ Because all calculations were performed stratum-wise, reference individuals whose index
individual with celiac disease had been excluded were also excluded.
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TABLE 1
Characteristics of the study participants.
Matched reference individuals Celiac disease
Total 143,746 28,908
Age at study entry, years (median, range) 30; 0–95 30; 0–95
Age 10–19 (%) 58,843 (40.9) 11,799 (40.8)
Age 20–39 (%) 26,290 (18.3) 5,284 (18.3)
Age 40–59 (%) 31,932 (22.2) 6,404 (22.2)
Age ≥60 (%) 26,681 (18.6) 5,421 (18.8)
Entry year (median, range) 1998; 1969–2008 1998; 1969–2008
Follow-up#, years (median, range) 10; 0–41 10; 0–41
Follow-up#, years (mean±SD) 11.4±6.5 11.2±6.5
Females (%) 89,204 (62.1) 17,926 (62.0)
Males (%) 54,542 (37.9) 10,982 (38.0)
Calendar year
-1989 20,302 (14.1) 4,088 (14.1)
1990–99 59,553 (41.4) 11,986 (41.5)
2000- 63,891 (44.4) 12,834 (44.4)
Country of birth, Nordic 135,549 (94.3) 27,961 (96.7)
*Ages were rounded to the nearest year.
#
Follow-up time until diagnosis of pancreatitis, death, emigration, or 31 December 2009. In reference individuals follow-up can also end through
small intestinal biopsy.
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